financetom
Business
financetom
/
Business
/
UK's Thames Water set for over $13.5 billion rescue deal by Silver Point and Elliott, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK's Thames Water set for over $13.5 billion rescue deal by Silver Point and Elliott, Bloomberg News reports
Jun 6, 2025 12:44 PM

(Reuters) -U.S. investment firms Silver Point Capital and Elliott Management are formulating a 10-billion-pound-plus ($13.53 billion) rescue package for Britain's Thames Water, Bloomberg News reported on Friday, citing people familiar with the matter.

The deal will comprise a major debt overhaul, including a multi-billion-pound haircut for senior creditors, in addition to reductions already expected for junior Class B bonds, loans and around 3 billion pounds in holding company debt, the report said.

The rescue package will provide an equity boost of between 3 billion pounds and 4 billion pounds to stabilize the utility's finances, according to the report.

"The Creditors have submitted a detailed long-term turnaround plan that will fix the root causes of Thames Water's problems, restore its balance sheet, rebuild customer trust and fix the fundamentals of the business once and for all," a spokesperson for the creditors, which include Silver Point Capital and Elliott, said in an emailed statement to Reuters.

Thames Water did not immediately respond to a request for comment.

Thames Water suffered a major setback on Tuesday in its fight to avoid nationalisation, as it said U.S. private equity firm KKR had pulled out of a multi-billion-pound rescue plan.

Britain's biggest water supplier is at the centre of a public backlash against the privatised water sector, which has been blamed for polluting Britain's rivers and seas while hiking bills and prioritising dividend payouts over infrastructure investment.

($1 = 0.7393 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thermal tech firm Gentherm posts higher Q3 revenue, raises guidance 
Thermal tech firm Gentherm posts higher Q3 revenue, raises guidance 
Oct 23, 2025
Overview * Gentherm ( THRM ) Q3 revenue rises 4.1% to $387 mln, adjusted EBITDA beats estimates * Company secured $745 mln in automotive new business awards in Q3 * Gentherm ( THRM ) raises 2025 full-year revenue guidance midpoint Outlook * Gentherm ( THRM ) raises full-year 2025 revenue guidance to $1.47 bln-$1.49 bln * Adjusted EBITDA margin guidance...
Tri Pointe Homes Q3 sales falls 26.6% as prices drop
Tri Pointe Homes Q3 sales falls 26.6% as prices drop
Oct 23, 2025
Overview * Tri Pointe Q3 home sales revenue falls 26.6% yr/yr to $817.3 mln * Net income for Q3 drops 49.8% to $56.1 mln * Company repurchased $51 mln of common stock Outlook * Tri Pointe Homes ( TPH ) expects Q4 home deliveries between 1,200 and 1,400 units * Company anticipates Q4 average sales price between $690,000 and $700,000...
Utility PG&E beats Q3 adjusted EPS estimates, narrows FY profit forecast
Utility PG&E beats Q3 adjusted EPS estimates, narrows FY profit forecast
Oct 23, 2025
Overview * PG&E ( PCG ) Q3 operating revenue missed analyst expectations * Adjusted EPS for Q3 beats analyst estimates * GAAP EPS for Q3 increased to $0.37 from $0.27 in 2024 Outlook * PG&E ( PCG ) narrows 2025 non-GAAP core EPS guidance to $1.49-$1.51 * Company initiates 2026 non-GAAP core EPS guidance of $1.62-$1.66 * PG&E ( PCG...
India's Cipla signs pact with Lilly to sell weight loss drug tirzepatide in India
India's Cipla signs pact with Lilly to sell weight loss drug tirzepatide in India
Oct 23, 2025
Oct 23 (Reuters) - Indian drugmaker Cipla signed an agreement with Eli Lilly ( LLY ) to sell tirzepatide, the active ingredient in the U.S. company's blockbuster weight-loss drug Mounjaro, in India, the companies said on Thursday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved